Nanomedicine laboratory

Nanomedicine laboratory - major publications

• Durand A, Gréa T, Lebeau G, Jacquot G, Tillement A, Aigle A, Thomas E, Kryza D, Taleb J, Ferrauto G, Gianolio E, Géloen A, Montembault A, Guttierez-Blanco M, Pivot X, Harlepp S, Detappe A, David L†, Lux F†, Tillement O^†. “Functionalization of chitosan with polycarboxylic macrocycle yields injectable hydrogel with pH and salts responsiveness”. Mater Today Adv, 2025.
• Jacquot G, Lopez Navarro P, Grange C, Boudali L, Harlepp S, Pivot X, Detappe A. “Landscape of subcutaneous administration strategies for monoclonal antibodies in oncology”. Adv Mat, 2024
• Mathieu C, Ghosh S, Draussin J, Gasser A, Jacquot G, Banerjee M, Gupta T, Schmutz M, Mirjolet C, Tillement O, Lux F, Klymchenko A, Donzeau M, Pivot X, Harlepp S, Detappe A. “Supramolecular heterodimer peptides assembly for nanoparticles functionalization” Adv Healthc Mater, 2024 (featured in the cover of the issue)
• Grea T, Jacquot G, Durand A, Mathieu C, Gasser A, Zhu C, Banerjee M, Hucteau E, Mallard J, Brichard T, Thomas E, Ferrauto G, Gianolio E, Fleith G, Combet J, Braun S, Erb S, Cianferani S, Charbonniere LJ, Mirjolet C, David L, Harlepp S, Tillement O, Lux F, Pivot X, Detappe A. “Zwitterionic chitosan-based hydrogel formulation for subcutaneous administration of monoclonal antibodies”. Adv Mat, 2023 (featured in the cover of the issue)
• Cui G, Botuyan MV, Drané P, Hu Q, Bragantini B, Thompson JR, Schuller DJ, Detappe A, Perfetti MT, James LI, Frye SV, Chowdhury D, Mer G^†. “An autoinhibited state of 53BP1 revealed small molecule antagonists and protein engineering”. Nat Commun, 2023
• Lena C, Banerjee M, Coliat P, Harlepp S, Pivot X, Tillement O, Lux F, Detappe A. “Toward clinical transfer of tumor-targeted ultrasmall inorganic nanoparticles”. Adv Therapeutics, 2023 (featured in the cover of the issue)
• Diringer MC, Coliat P, Mathieu C, Laurent N, Zhu C, Mura C, Banerjee M, Grabowska A, Ritchie A, Clarke P, Bernard A, Vit C, Burckel H, Noel G, Harvey P, Pivot X, Detappe A. “Clinically translatable transcrocetin delivery platform for correction of tumor hypoxia and enhancement of radiation therapy effects”. Small, 2023 Jan 1:e2205961 (featured in the cover of the issue)
• Detappe A, Nguyen HVTN, Jiang Y, Agius P, Wang W, Mathieu C, Su NK, Kristufek SL, Lundberg DJ, Bhagchandani S, Ghobrial IM, Ghoroghchian PP, Johnson JA. “Molecular bottlebrush prodrugs as next-generation mono and triplex combination therapies for multiple myeloma”. Nat Nanotechnol, 2023 Feb;18(2):184-192
• Mittelheisser V, Coliat P, Moeglin E, Goepp, Goetz JG, Charbonnière LJ, Pivot X, Detappe A “Optimal physicochemical properties of antibody-nanoparticle conjugates for improved tumor targeting” Adv Mat. 2022 Jun;34(24):e2110305
• Thomas E, Mathieu C, Lux F, Tillement O, Pivot X, Ghoroghchian PP, Detappe A “Anti-BCMA immune-nanoPET tracer for improved detection of Multiple Myeloma” Adv Healthc Mater. 2021 Oct 28:e2101565.